

Diabetes Intelligence Report

Type 1 · Type 2 · GLP-1 · CGM · Diabetic Foot · Vision 2030

● LIVE INGEST

Last refresh — 07 May 2026 21:29:20Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <p>1,568</p> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <p>4 / 6</p> <p>Of 6 wired</p>	<p>COMPANIES MONITORED</p> <p>49</p> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH</p> <p>160</p> <p>Material signals (90d)</p>
--	---	--	--

RISK REGISTER · THE COST OF SEEING LATE Adversarial verification scope

Three exposures every diabetes portfolio carries today.

Reimbursement Cycle Risk

GLP-1, SGLT2, and CGM coverage decisions in flight across the 2025–2026 cycle will reshape roughly \$40B in run-rate revenue. Live formulary and CMS LCD signals are tracked across the indexer.

CALIBRATING · NEXT REFRESH

AdComm Lag Risk

PubMed signals indexed in the 90-day window. The lag between AdComm vote and equity repricing is where investors not on the dispatch sheet pay yesterday's price.








999

Sovereign Procurement Risk

KSA, GCC, and MENA diabetes manufacturers under continuous monitoring. Vision 2030 procurement windows close every 18 months — missing one means missing a cycle.

6 / 49

What we are watching

FDA openFDA		191
ClinicalTrials.gov		225
PubMed		999
SEC EDGAR		153
CMS LCD		0
USPTO Patents		0
Manufacturer Pipelines		0

Top 10 by severity and recency

PUBMED CRITICAL 2026-04-29

Self-Cascading Copper-Based Nanoassemblies Trigger Bacterial Cuproptosis-Like Death and Promote Wound Healing for Diabetic Drug-Resistant Bacterial Infections.

Feng T

Self-Cascading Copper-Based Nanoassemblies Trigger Bacterial Cuproptosis-Like Death and Promote Wound...

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Pulmonary mucormycosis with endobronchial involvement due to *Rhizopus homothallicus*: a fatal case report.

Hernández-Solís A

Pulmonary mucormycosis with endobronchial involvement due to *Rhizopus homothallicus*: a fatal case report.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Fatal *Escherichia coli* Necrotizing Fasciitis in a Patient With End-Stage Renal Disease and Type 2 Diabetes Mellitus.

Clark CA

Fatal *Escherichia coli* Necrotizing Fasciitis in a Patient With End-Stage Renal Disease and Type 2 Diabetes Mellitus.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Fatal metformin-associated lactic acidosis in a healthy woman after massive overdose.

Unal Kaya E

Fatal metformin-associated lactic acidosis in a healthy woman after massive overdose.

[PubMed \(NCBI E-utilities\) ↗](#)

PUBMED CRITICAL 2026-01-01

Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a prospective, observational, population-based analysis of adults with diabetes in Mexico City.

Perezalonso-Espinosa J

Assessment of fatal cardiovascular disease risk using data-driven diabetes subgroups and SCORE2-Diabetes: a...

[PubMed \(NCBI E-utilities\) ↗](#)

FDA CRITICAL 2016-08-17

HeartWare Ventricular Assist System (HVAD), US product: Model No.: 1103; and International Product: Model No.: 1104XX. Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter.

HeartWare, Inc

Foreign material found within the driveline connector of the HVAD Pump that could cause increased impedance resultin...

[U.S. Food & Drug Administration ↗](#)

FDA CRITICAL 2016-06-08

HeartWare Ventricular Assist System Controller Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HVAD is designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter

Heartware, Inc.

Loose connector ports in controller body.

[U.S. Food & Drug Administration](#)

FDA CRITICAL 2009-09-22

Penumbra Neuron Delivery Catheter 070, percutaneous catheter, catalog numbers PND6F070I058, PND6F070956, PND6F070I058M, and PND6F070956M; manufactured by Penumbra, Inc., Alameda, CA. Indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

Penumbra Inc.

Failure-- product can kink or ovalize, which may result in difficulty in catheter advancement or delivery of other...

[U.S. Food & Drug Administration](#)

SEC HIGH 2026-05-07

LLY — 8-K filing

LLY

8-K

[SEC EDGAR](#)

SEC HIGH 2026-05-07

TNDM — 8-K filing

TNDM

8-K

[SEC EDGAR](#)

Reimbursement watchlist

CMS & FORMULARY COVERAGE · 2025-2026

GLP-1, SGLT2, and CGM coverage decisions are reshaping the diabetes economics base.

Coverage and formulary decisions on GLP-1 receptor agonists for type 2 diabetes and obesity, SGLT2 inhibitors with cardiorenal indications, and continuous glucose monitors for type 1 and intensively managed type 2 populations are in active rewrite across CMS and the major commercial PBMs. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.

Saudi Arabia • Vision 2030

SOVEREIGN VECTOR • KSA / VISION 2030

Saudi Arabia carries one of the highest diabetes prevalence rates among adults globally. The Ministry of Health has positioned amputation reduction as a Vision 2030 priority.

The GCC + MENA cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's diabetes intelligence layer. SFDA approvals, MOH formulary movements, and cross-border clinical infrastructure across Riyadh, Jeddah, Dubai, Abu Dhabi, Amman, and Cairo are already trackable through the indication-aware pipeline.

Decisions of this scale — coverage policy, capital procurement of GLP-1 supply, CGM rollout to primary care, and diabetic-foot prevention programs — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.

~18%

Adult diabetes prevalence, KSA

5 / 49

Sovereign-tagged manufacturers monitored

~\$40B

Global GLP-1 + SGLT2 + CGM run-rate exposure

7

Public sources triangulated per signal class

SOVEREIGN ROSTER • KSA / GCC / MENA

<p>SPIMACO Riyadh, SA</p> <p>KSA</p>	<p>Tabuk Pharmaceuticals Tabuk, SA</p> <p>KSA</p>	<p>Jamjoom Pharma Jeddah, SA</p> <p>KSA</p>	<p>Julphar Ras Al Khaimah, AE</p> <p>GCC</p>	<p>Hikma Pharmaceuticals Amman, JO</p> <p>MENA</p>
---	--	--	---	---

Monitored issuers and operators

<p>Eva Pharma Cairo, EG</p> <p>MENA</p>	<p>Hikma Pharmaceuticals HIK Amman, JO</p> <p>MENA</p>	<p>Jamjoom Pharma Jeddah, SA</p> <p>KSA</p>
<p>Julphar Ras AL Khaimah, AE</p> <p>GCC</p>	<p>SPIMACO Riyadh, SA</p> <p>KSA</p>	<p>Tabuk Pharmaceuticals Tabuk, SA</p> <p>KSA</p>
<p>Abbott Diabetes Care ABT Alameda, CA</p> <p>MEDTECH</p>	<p>AbbVie ABBV North Chicago, IL</p> <p>BIGPHARMA</p>	<p>Adocia Lyon, FR</p> <p>BIOTECH</p>
<p>Akero Therapeutics AKRO South SF, CA</p> <p>BIOTECH</p>	<p>Altimune ALT Gaithersburg, MD</p> <p>BIOTECH</p>	<p>Aspen Pharmacare Durban, ZA</p> <p>BIGPHARMA</p>
<p>AstraZeneca Diabetes AZN Cambridge, UK</p> <p>BIGPHARMA</p>	<p>Bayer Diabetes Leverkusen, DE</p> <p>BIGPHARMA</p>	<p>BeiGene Diabetes BGNE Beijing, CN</p> <p>BIGPHARMA</p>
<p>Beta Bionics Irvine, CA</p> <p>MEDTECH</p>	<p>Bigfoot Biomedical Milpitas, CA</p> <p>EMERGING</p>	<p>Boehringer Ingelheim Ingelheim, DE</p> <p>BIGPHARMA</p>
<p>Carmot Therapeutics Berkeley, CA</p> <p>BIOTECH</p>	<p>Dexcom DXCM San Diego, CA</p> <p>MEDTECH</p>	<p>DiaMedica DMAC Minneapolis, MN</p> <p>BIOTECH</p>
<p>Diasome Cleveland, OH</p> <p>EMERGING</p>	<p>Eli Lilly LLY Indianapolis, IN</p> <p>BIGPHARMA</p>	<p>Embecta EMBC Parsippany, NJ</p> <p>MEDTECH</p>
<p>EMS Pharma Sao Paulo, BR</p> <p>BIGPHARMA</p>	<p>Eurofarma Sao Paulo, BR</p> <p>BIGPHARMA</p>	<p>Hanmi Pharmaceutical Seoul, KR</p> <p>BIGPHARMA</p>
<p>Hua Medicine Shanghai, CN</p> <p>BIOTECH</p>	<p>Innovent Biologics Suzhou, CN</p> <p>BIOTECH</p>	<p>Insulet PODD Acton, MA</p> <p>MEDTECH</p>

Intarcia Therapeutics Boston, MA EMERGING	Lexicon Pharmaceuticals LXRX The Woodlands, TX BIOTECH	Lupin Diabetes Mumbai, IN BIGPHARMA
Mannkind MNKD Westlake Village, CA BIOTECH	Medtronic Diabetes MDT Northridge, CA MEDTECH	Merck (Januvia) MRK Rahway, NJ BIGPHARMA
Novo Nordisk NVO Bagsvaerd, DK BIGPHARMA	Oramed ORMP Jerusalem, IL BIOTECH	Pfizer Diabetes PFE New York, NY BIGPHARMA
Provention Bio Red Bank, NJ BIOTECH	Roche Diagnostics Basel, CH BIGPHARMA	Sanofi SNY Paris, FR BIGPHARMA
Senseonics SENS Germantown, MD MEDTECH	Sernova London, ON, CA MEDTECH	Sun Pharma Diabetes Mumbai, IN BIGPHARMA
Tandem Diabetes Care TNDM San Diego, CA MEDTECH	Vertex Diabetes VRTX Boston, MA BIOTECH	vTv Therapeutics VTVT High Point, NC BIOTECH
Ypsomed Burgdorf, CH MEDTECH		

06 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

Volume & cadence of public disclosure



METHODOLOGY

This report is generated from a live ingest pipeline (`tools/scout-ingest`). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated 07 May 2026 21:29:20Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.